A triple-negative breast cancer surrogate subtype classification that correlates with gene expression subtypes

Background This study developed a triple-negative breast cancer (TNBC) surrogate subtype classification that represents TNBC subtypes based on the Vanderbilt subtype classification. Methods Patients who underwent primary curative surgery for TNBC were included. Representative FFPE blocks were used f...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2022-02, Vol.191 (3), p.599-610
Main Authors: Yoo, Tae-Kyung, Kang, Jun, Lee, Awon, Chae, Byung Joo
Format: Article
Language:English
Subjects:
Analysis
Androgen receptors
Androgens
Breast cancer
Breast Neoplasms
Cancer
Cancer research
Classification
Clinical Trial
DNA microarrays
Female
Gene Expression
Genes
Genetic aspects
Humans
Immunomodulation
Lymphocytes
Lymphocytes, Tumor-Infiltrating
Medical research
Medicine
Medicine & Public Health
Medicine, Experimental
Mesenchyme
Oncology
Patients
Stem cells
Triple Negative Breast Neoplasms - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background This study developed a triple-negative breast cancer (TNBC) surrogate subtype classification that represents TNBC subtypes based on the Vanderbilt subtype classification. Methods Patients who underwent primary curative surgery for TNBC were included. Representative FFPE blocks were used for gene expression analysis and tissue microarray construction for immunohistochemical (IHC) staining. The Vanderbilt subtypes were re-classified into four groups: basal-like (BL), mesenchymal-like (M), immunomodulatory (IM) and luminal androgen receptor (LAR) subtype. Classification and regression tree (CART) modeling was applied to develop a surrogate subtype classification. Results A total of 145 patients were included. The study cohort was allocated to the Vanderbilt 4 subtypes as LAR ( n  = 22, 15.2%), IM ( n  = 32, 22.1%), M ( n  = 38, 26.2%), BL ( n  = 25, 17.2%) and unclassified ( n  = 28, 19.3%). After excluding nine (6.2%) patients due to poor IHC staining quality, CART modeling was performed. TNBC surrogate subtypes were defined as follows: LAR subtype, androgen receptor Allred score 8; IM subtype, LAR-negative with a tumor-infiltrating lymphocyte (TIL) score > 70%; M subtype, LAR-negative with a TIL score 
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-021-06437-8